This spontaneous case, described in the literature, concerns an adult patient of unreported age, gender and origin. 
The patient's medical history was not reported. Concomitantmedications included ca   a n.  -tin, bevacizumab, folic 
acid, vitamin B12 and dexamethasone. The patient received pemetrexed (Alimta), 500 mg/m2, in combination 
with carboplatin 6 area under the concentration-time curve (AUC), and bevacizumab 15 mg/kg, per intravenous (IV) 
infusion on. day one every three weeks, beginning on an unrze     =0 date for-the treatment of advanced non-small 
cell lung cancer (NSCLC). On an unspecified date while on study, the patient experienced pneumonia and expired. 
Corrective interventions were not reported. It was not reported if an autopsy was performed. The authors stated 
that the pneumonia with sub . t death was possibly treatment related. This case is linked to 
US200907002835, U5200907004 -5.35, US2009070044636, and US20090.7004538. This case was descrived in the 
article: Patel J, Hensing T, Raclernaker A, Hart E, Blum M, Milton D and Bonomi P. Phase II Study of Pernetrexed 
and Carbopiatin Plus Bevacixumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer. Journal 
of Clinical Oncology. 2000; 27(20): 3284-3289. 
Print rem 02-SEP-2014 11:09 AM If a field is blank, there is no data for that field Page 556 of 661 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information